Online inquiry

IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15383MR)

This product GTTS-WQ15383MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15383MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1913MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ3115MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ14667MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ14781MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ7684MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ13358MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ15697MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ11714MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MILR1444A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW